Abstract
Objectives Hypothalamic-pituitary-adrenal (HPA) dysregulation is a postulated risk factor for cardiovascular disease but results from previous studies have been mixed. We examined cross-sectional associations of diurnal patterns of salivary cortisol with 10 subclinical measures of cardiovascular disease (including pulse wave velocity, carotid intima-media thickness, and measures of heart structure and function), and prospective associations of cortisol variation with cardiovascular (CV) and non-cardiovascular (NCV) mortality.
Methods We included up to 1,263 participants of the MRC National Survey for Health and Development birth cohort, who had participated in serial diurnal salivary cortisol sampling in 2006-2010 (aged 60–64 years). We used multivariable linear and multinomial logistic regression to estimate associations of cortisol awakening response (CAR), slope and area under the curve (AUC) with subclinical cardiovascular measures, and multivariable Cox regression to estimate associations of the three cortisol metrics with all-cause, CV and NCV mortality.
Results All associations with subclinical cardiovascular measures were weak and most were compatible with the null hypothesis. Each standard deviation (SD) higher cortisol AUC was associated with a 1.9% (95%-CI 0.3-3.5) higher pulse wave velocity. A shallow cortisol slope (per SD gradient) was associated with a 1.4% lower intima media thickness (95%-CI −2.6, − 0.2), and lower odds of concentric remodelling (OR 0.83, 95%-CI 0.70-0.99). Given the multiple analyses performed, these could be chance findings. AUC, cortisol slope and CAR were not convincingly associated with cardiovascular or total mortality, although the 95% confidence intervals of hazard ratio estimates were wide.
Conclusions This study provides little evidence for clinically important associations of salivary cortisol and subclinical cardiovascular measures and mortality.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the Medical Research Council (MC_UU_00019/2).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Various. As per the publication describing the cohort's data collection (https://academic.oup.com/ije/article/40/1/e1/661817): "Ethical approval was given by the Central Manchester Research Ethics Committee for the data collection taking place in Manchester, Birmingham, Cardiff and London. Ethical approval was given by the Scottish A Research Ethics Committee for the data collection taking place in Edinburgh."
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data used in this publication are available to bona fide researchers upon request to the NSHD Data Sharing Committee via a standard application procedure. Further details can be found at http://www.nshd.mrc.ac.uk/data